HLS Therapeutics Inc. updated consolidated revenue guidance for the full year 2024. for the year, the company is lowering its full year consolidated revenue guidance to a range of $60 million - $62 million from $63.5 million -$66.5 million.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.72 CAD | -7.00% | +0.54% | -5.82% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-5.82% | 86.87M | |
+23.06% | 74.5B | |
-2.97% | 24.24B | |
+9.92% | 8.45B | |
+4.65% | 8.44B | |
-23.66% | 7.65B | |
+11.90% | 5.24B | |
+2.41% | 4.14B | |
-6.90% | 3.95B | |
+3.99% | 3.83B |
- Stock Market
- Equities
- HLS Stock
- News HLS Therapeutics Inc.
- HLS Therapeutics Inc Updates Consolidated Revenue Guidance for the Full Year 2024